The FDA's "radical transparency", up to a point
A newly published cache of CRLs includes six novel oncology drugs.
A newly published cache of CRLs includes six novel oncology drugs.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ESO-T01 delivers its first four multiple myeloma case reports.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.